PMC7378529_01
Baseline computed tomography (CT) showing a lung mass in the left lower lobe pulmonary window (A) and mediastinal window (C), and an enlarged left lower paratracheal (4L) lymph node (E); CT images after two cycles of four drug combination therapy showing partial response in the pulmonary window (B) and mediastinal window (D), and a significantly reduction in the 4L lymph node (F).
fonc-10-01145-g0001.jpg
PMC7378529_01_fonc-10-01145-g0001.jpg
F1
Computed tomography (CT) revealed a lung mass in the left lower lobe (Figures 1A,C) and multiple hilar and mediastinal lymph nodes (Figure 1E). After two cycles of neoadjuvant therapy, the Positron emission tomography/Computed tomography (PET/CT) revealed that the tumor was reduced from 4.6 x 2.0 cm to 1.4 x 1.1 cm (Figures 1B,D) with a normal standard uptake value (SUV), and there were no enlarged mediastinal or hilar lymph nodes (Figure 1F).
The HE showed an increase in the number of residue cancer cells, but fibrosis still predominated in 20x (A) and in 40x (B).
fonc-10-01145-g0002.jpg
PMC7378529_01_fonc-10-01145-g0002.jpg
F2
It was characterized by an increase in the number of residue cancer cells, but fibrosis still predominated (Figures 2A,B).
The timeline showing the relevant data of treatment.
fonc-10-01145-g0003.jpg
PMC7378529_01_fonc-10-01145-g0003.jpg
F3
The timeline of treatment with relevant data of care was shown in Figure 3.